Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors

Patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutations usually have a good response rate (RR) and longer progression-free survival (PFS) to EGFR tyrosine kinase inhibitors (TKIs). However, the treatment efficacy to uncommon EGFR mutations remains controv...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Ming-Ju, Hung, Jen-Yu, Lee, Mei-Hsuan, Kuo, Chia-Yu, Tsai, Yu-Chen, Tsai, Ying-Ming, Liu, Ta-Chih, Yang, Chih-Jen, Huang, Ming-Shyan, Chong, Inn-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266446/
https://www.ncbi.nlm.nih.gov/pubmed/30428509
http://dx.doi.org/10.3390/cancers10110434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266446/
https://www.ncbi.nlm.nih.gov/pubmed/30428509
http://dx.doi.org/10.3390/cancers10110434

Ejemplares similares